CD28 and acute myeloid leukemia: Based on this experience, cellular persistence may be better achieved through the use of 4-1BB-containing CAR constructs over those containing CD28 costimulatory domains albeit with a higher risk of antigen-escape, thereby invoking the need for multi-target approaches to maximize clinically durable benefit in AML.